Jorg Kraus
Overview
Explore the profile of Jorg Kraus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Etzdorf A, Harzen M, Heinrichs H, Seifert H, Groiss S, Balloff C, et al.
Front Hum Neurosci
. 2024 Dec;
18:1468204.
PMID: 39677403
Background: The majority of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only show mild respiratory symptoms. However, some patients with SARS-CoV-2 display neurological symptoms. Data on the...
2.
Hegen H, Berek K, Deisenhammer F, Berger T, Enzinger C, Guger M, et al.
J Neurol
. 2024 Mar;
271(6):3256-3267.
PMID: 38441611
Background: Individual disease-modifying treatment (DMT) decisions might differ between female and male people with MS (pwMS). Objective: To identify sex-related differences in DMT strategies over the past decades in a...
3.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, et al.
J Neurol
. 2024 Mar;
271(6):3142-3152.
PMID: 38430270
Objectives: To compare the effectiveness of early intensive treatment (EIT) versus escalation treatment (ESC) in a nationwide observational cohort of almost 1000 people with relapsing-remitting multiple sclerosis (RRMS). Materials And...
4.
Zinganell A, Gobel G, Berek K, Hofer B, Asenbaum-Nan S, Barang M, et al.
J Neurol
. 2023 Oct;
271(2):674-687.
PMID: 37855871
Background: There is a lack of knowledge of disease course, prognosis, comorbidities and potential treatments of elderly MS patients. Objective: To characterize the disease course including disability progression and relapses,...
5.
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, et al.
J Neurol
. 2023 Jun;
270(8):3787.
PMID: 37272963
No abstract available.
6.
Monschein T, Dekany S, Zrzavy T, Ponleitner M, Altmann P, Bsteh G, et al.
J Neurol
. 2023 Apr;
270(8):3779-3786.
PMID: 37074388
Introduction: With the approval of natalizumab in Europe in 2006, the Austrian Multiple Sclerosis Therapy Registry (AMSTR) was established. Here, we present data from this registry about effectiveness and safety...
7.
Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S, et al.
J Neurol
. 2023 Mar;
270(6):3103-3111.
PMID: 36862148
Objectives: To compare in a nationwide observational cohort the effectiveness, frequency and reasons for treatment interruption of dimethylfumarate (DMF) and teriflunomide (TERI) (horizontal switchers) versus alemtuzumab (AZM), cladribine (CLAD), fingolimod...
8.
Arneth B, Kraus J
Medicina (Kaunas)
. 2022 Nov;
58(11).
PMID: 36363469
: The positive implications of using free light chains in diagnosing multiple sclerosis have increasingly gained considerable interest in medical research and the scientific community. It is often presumed that...
9.
Arneth B, Kraus J
Wien Med Wochenschr
. 2022 Mar;
172(15-16):346-358.
PMID: 35254566
Background: Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system; the cause of this condition remains unknown. Researchers have analyzed different biomarkers related to MS. Here,...
10.
Moser T, OSullivan C, Puttinger C, Feige J, Pilz G, Haschke-Becher E, et al.
Biomedicines
. 2021 Nov;
9(11).
PMID: 34829815
Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study...